These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34607367)

  • 1. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
    Altuntaş SÇ; Hocaoğlu Ç
    Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
    Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
    Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
    Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
    [No Abstract]   [Full Text] [Related]  

  • 4. Adequate Dose of Levothyroxine for Thyroid-Stimulating Hormone Suppression after Total Thyroidectomy in Patients with Differentiated Thyroid Cancer.
    Ryu HJ; Choi MS; Park H; Kim TH; Chung JH; Park SY; Kim SW
    Endocrinol Metab (Seoul); 2024 Aug; 39(4):615-621. PubMed ID: 39111780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients.
    Yavuz DG; Yazan CD; Hekimsoy Z; Aydin K; Gokkaya N; Ersoy C; Akalın A; Topaloglu O; Aydogan BI; Dilekci ENA; Alphan Uc Z; Cansu GB; Ozsari L; Iyidir OT; Olgun ME; Keskin L; Mert M; Can B; Gungor K; Galip T; Cantürk Z; Elbuken G; Pekkolay Z; Kutbay NO; Yorulmaz G; Kalkan AT; Unsal YA; Yay A; Karagun B; Bozkur E
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):833-840. PubMed ID: 35639050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients.
    Ito M; Miyauchi A; Hisakado M; Yoshioka W; Kudo T; Nishihara E; Kihara M; Ito Y; Miya A; Fukata S; Nishikawa M; Nakamura H
    Endocr J; 2019 Nov; 66(11):953-960. PubMed ID: 31270299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
    Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
    Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma.
    Gülsoy Kirnap N; Turhan Iyidir Ö; Bozkuş Y; Işildak ŞM; Anil C; Firat SN; Demir C; Nar A; Başçil Tütüncü N
    Turk J Med Sci; 2020 Jun; 50(4):870-876. PubMed ID: 32490648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy.
    Baran J; Isaza A; Bojarsky M; Alzoebie L; Song M; Halada S; Sisko L; Gonzales S; Mostoufi-Moab S; Bauer AJ
    Front Endocrinol (Lausanne); 2024; 15():1443394. PubMed ID: 39205688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
    Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
    J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Na YM; Cho JS; Park MH
    Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
    Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
    J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
    Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
    Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
    Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Levothyroxine Replacement or Suppressive Therapy on Energy Expenditure and Body Composition.
    Samuels MH; Kolobova I; Smeraglio A; Peters D; Purnell JQ; Schuff KG
    Thyroid; 2016 Mar; 26(3):347-55. PubMed ID: 26700485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Resistance to Exogenous Thyroxine in Humans.
    Lacámara N; Lecumberri B; Barquiel B; Escribano A; González-Casado I; Álvarez-Escolá C; Aleixandre-Blanquer F; Morales F; Alfayate R; Bernal-Soriano MC; Miralles R; Yildirim Simsir I; Özgen AG; Bernal J; Berbel P; Moreno JC
    Thyroid; 2020 Dec; 30(12):1732-1744. PubMed ID: 32498666
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy.
    Brun VH; Eriksen AH; Selseth R; Johansson K; Vik R; Davidsen B; Kaut M; Hellemo L
    Thyroid; 2021 Sep; 31(9):1297-1304. PubMed ID: 33980057
    [No Abstract]   [Full Text] [Related]  

  • 20. Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.
    Freudenthal B; Williams GR
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):325-328. PubMed ID: 28043744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.